Adjuvant ado-trastuzumab emtansine provides 'transformative' benefit for certain patients with HER2-positive breast cancer

December 06, 2018 8:21 AM | Grant Dvorak (Administrator)
December 6, 2018, HemOnc Today 

Adjuvant ado-trastuzumab emtansine reduced risk for invasive recurrence by 50 percent compared with trastuzumab among patients with HER2-positive early breast cancer who still had residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy, according to results of the KATHERINE trial presented at San Antonio Breast Cancer Symposium. 

Read more.

Powered by Wild Apricot Membership Software